GI Innovation Inc
KOSDAQ:358570
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
8 440
24 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
GI Innovation Inc
Net Change in Cash
GI Innovation Inc
Net Change in Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
GI Innovation Inc
KOSDAQ:358570
|
Net Change in Cash
₩6.2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Net Change in Cash
₩611.2B
|
CAGR 3-Years
33%
|
CAGR 5-Years
28%
|
CAGR 10-Years
54%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Net Change in Cash
-₩98.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-120%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Net Change in Cash
₩53B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Net Change in Cash
₩50.8B
|
CAGR 3-Years
74%
|
CAGR 5-Years
59%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Net Change in Cash
₩4.6B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
62%
|
CAGR 10-Years
N/A
|
|
GI Innovation Inc
Glance View
GI Innovation, Inc. engages in the development of biopharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 88 full-time employees. The company went IPO on 2023-03-30. The firm is engaged in the business of generating revenue through license fees by technology transfer of new drug candidates in pre-clinical and early clinical stages. The core new drug pipeline includes products such as GI-101 immuno-oncology and GI-301 allergy treatment.
See Also
What is GI Innovation Inc's Net Change in Cash?
Net Change in Cash
6.2B
KRW
Based on the financial report for Dec 31, 2023, GI Innovation Inc's Net Change in Cash amounts to 6.2B KRW.
What is GI Innovation Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 3Y
8%
Over the last year, the Net Change in Cash growth was 1 443%. The average annual Net Change in Cash growth rates for GI Innovation Inc have been 8% over the past three years .
You don't have any saved screeners yet
